TY  - JOUR
AB  - BACKGROUND AND OBJECTIVES: Venom immunotherapy (VIT) and natural exposure to Hymenoptera venom induce immune tolerance in allergic patients and beekeepers, respectively. Specific IgE (sIgE) and IgG4 (sIgG4) antibodies play crucial roles in allergic reactions and immune tolerance. To investigate the dynamics of sIgE and sIgG4 responses to Hymenoptera venom in patients undergoing VIT and in nonallergic beekeepers at a component-resolved level. METHODS: Serum samples from patients allergic to honeybee venom (HBV) or yellow jacket venom (YJV) and from beekeepers were collected during the first year of VIT and before and after the beekeeping season, respectively. sIgE and sIgG4 levels to whole venom and molecular allergens were measured using the ImmunoCAP platform. RESULTS: Pronounced sIgE and sIgG4 responses to Ves v 1 and 5 in YJV-allergic patients were accompanied by more frequent sensitization to Ves v 1 after up-dosing. While sIgE profiles in HBV-allergic patients were highly diverse, with a marked contribution of Api m 1 and Api m 10 sIgE, the sIgG4 response during VIT was strongly dominated by Api m 1. Different VIT preparations did not significantly affect the sIgG4 response to low-abundance HBV allergens. In beekeepers, induction of sIgG4 was dependent on sting frequency and was dominated by Api m 1. CONCLUSIONS: Robust induction of IgG4 during VIT and natural venom exposure occurs primarily to abundant allergens and is unaffected by the choice of VIT preparation. The effectiveness of VIT and beekeepers´ tolerance to HBV indicate that strong sIgG4 responses to lowabundance allergens are not crucial for immune tolerance.
AU  - Blank, S.
AU  - Dorn, B.*
AU  - Seiringer, P.*
AU  - Grosch, J.
AU  - Slusarenko, B.O.
AU  - Dittmar, M.
AU  - Kaczmarcyk, R.*
AU  - Rogner, D.*
AU  - Jung, A.*
AU  - Plail, L.*
AU  - Eberlein, B.*
AU  - Biedermann, T.*
AU  - Darsow, U.*
AU  - Brockow, K.*
AU  - Schmidt-Weber, C.B.
AU  - Jakob, T.*
C1  - 74840
C2  - 57630
TI  - Component-resolved IgE and IgG4 profiling reveals robust IgG4 responses 
      primarily to abundant Hymenoptera allergens during venom immunotherapy 
      and in beekeepers.
JO  - J. Invest. Allergol. Clin. Immunol.
PY  - 2025
SN  - 1018-9068
ER  - 

TY  - JOUR
AB  - BACKGROUND AND OBJECTIVES: Venom immunotherapy (VIT) is an effective treatment for yellow jacket venom (YJV) allergy. It is often based on mixtures of venom from different species. Recent taxonomic re-evaluation has revealed that widely used VIT preparations contain venom from Vespula alascensis, a North American species, rather than venom from the Palearctic Vespula vulgaris. To assess the allergenic relevance of V alascensis venom for European patients and evaluate its suitability for inclusion in VIT preparations. METHODS: The ability of V alascensis and V vulgaris venom to activate effector cells from YJV-allergic patients from Germany was compared using the basophil activation test. Patients' sIgE reactivity was assessed using ELISA, inhibition ELISA, CAP inhibition, and Western blot. Proteomic analysis of the venoms was also conducted. RESULTS: Basophil activation tests showed highly similar activation profiles for V alascensis and V vulgaris venoms. Moreover, ELISA and inhibition analyses revealed comparable overall sIgE reactivity for both venoms. In contrast, Western blot analysis demonstrated similar sIgE profiles for antigen 5 allergens, although phospholipase A1 allergens were differentially detected. Proteomic analysis revealed no differences in the major allergens of the 2 venoms. CONCLUSION: This study demonstrates the functional similarity between V alascensis and V vulgaris venoms in allergic responses. Moreover, it highlights the clinical relevance of V alascensis for YJV-sensitized European patients and supports its inclusion in YJV VIT preparations in Europe.
AU  - Slusarenko, B.O.
AU  - Borrmann, K.F.*
AU  - Knappe, C.
AU  - Vogel, J.*
AU  - Schnautz, B.
AU  - Kler, S.*
AU  - Biedermann, T.*
AU  - Brockow, K.*
AU  - Darsow, U.*
AU  - Carreno Velazquez, T.L.*
AU  - Francescato, E.*
AU  - Hewings, S.J.*
AU  - Kramer, M.F.*
AU  - Heath, M.D.*
AU  - Dittmar, G.*
AU  - Hilger, C.*
AU  - Peters, R.S.*
AU  - Schmidt-Weber, C.B.
AU  - Eberlein, B.*
AU  - Blank, S.
C1  - 76124
C2  - 58397
TI  - Assessing the allergenic relevance of Vespula alascensis venom: Implications for venom immunotherapy.
JO  - J. Invest. Allergol. Clin. Immunol.
PY  - 2025
SN  - 1018-9068
ER  - 

TY  - JOUR
AB  - BACKGROUND: The ImmunoCAP ISAC 112 platform is the only commercially available molecular allergy IgE multiplex test. Data on the comparison of this rather novel test with the molecular singleplex ImmunoCAP IgE platform are lacking. OBJECTIVE: To compare the multiplex ISAC 112 platform and the singleplex ImmunoCAP platform in regard to IgE to grass pollen allergens in untreated grass pollen-allergic patients in Germany. METHODS: Serum samples from 101 adults with grass pollen allergy were analyzed for specific IgE (sIgE) to 8 allergenic molecules from timothy grass pollen and to the 112 allergenic molecules included in the ISAC panel. The results for the multiplex and singleplex tests were subsequently analyzed statistically. RESULTS: Comparison of sIgE to grass pollen allergens detected by ISAC 112 and the singleplex ImmunoCAP assay revealed the following correlation coefficients: 0.88 (rPhl p 1), 0.96 (rPhl p 2), 0.70 (nPhl p 4), 0.94 (rPhl p 5b), 0.92 (rPhl p 6), 0.85 (rPhl p 11), and 0.78 (rPhl p 12). CONCLUSION: Molecular testing with ISAC 112 correlates well with the ImmunoCAP platform for respective molecular timothy grass pollen allergens.
AU  - Ahlgrim, C.*
AU  - Gutermuth, J.*
AU  - Onell, A.*
AU  - Borres, M.P.*
AU  - Schäffner, I.*
AU  - Darsow, U.
AU  - Pfab, F.
AU  - Brockow, K.
AU  - Ring, J.*
AU  - Behrendt, H.
AU  - Jakob, T.*
AU  - Huss-Marp, J.*
C1  - 46482
C2  - 37585
SP  - 190-195
TI  - Comparison of molecular multiplex and singleplex analysis of IgE to grass pollen allergens in untreated German grass pollen-allergic patients.
JO  - J. Invest. Allergol. Clin. Immunol.
VL  - 25
IS  - 3
PY  - 2015
SN  - 1018-9068
ER  - 

TY  - JOUR
AB  - Background: Only a few studies have analyzed the value of early sensitization in predicting the development of atopic disease. The relevance of low immunoglobulin (Ig) E antibody levels in this respect also remains unclear. Objective: To investigate the relevance of sensitization in 12-month-old children in the development of atopic disease by the age of 6 years. Methods: We analyzed data for 1290 children with a positive family history of atopy from the prospective, multicenter German Infant Nutritional Intervention (GINIplus) study and investigated the relationship between the presence of detectable specific IgE antibodies at the age of 12 months and the development of atopic disease by the age of 6 years. Results: In all, 10.9% of children analyzed developed sensitization. At the age of 6 years, 20.6% of children with early sensitization had eczema compared to 9.4% of those without (odds ratio [OR], 2.31; 95% confidence interval [CI), 1.42-3.74). The corresponding figures were 15.4% vs 7.3% for allergic rhinitis (OR, 2.22; CI, 1.31-3.78) and 10.2% vs 2.6% (OR, 3.93; 95% Cl, 1.98-7.76) for asthma. Children with early sensitization to aeroallergens had the greatest risk of subsequent atopic disease. Early sensitization did not increase risk in children without eczema within the first year of life. Very low specific IgE levels (0.18-0.34 kU/L) were not significantly associated with any of the outcomes analyzed. Conclusion: Sensitization to common food allergens and to aeroallergens in particular during the first year of life was found to be a strong predictor for the development of atopic disease by the age of 6 years in children with a positive family history of atopy.
AU  - Brockow, I.
AU  - Zutavern, A.
AU  - Hoffmann, U.*
AU  - Grubl, A.*
AU  - von Berg, A.*
AU  - Koletzko, S.*
AU  - Filipiak, B.
AU  - Bauer, C.P.*
AU  - Wichmann, H.-E.
AU  - Reinhardt, D.*
AU  - Berdel, D.*
AU  - Krämer, U.*
AU  - Heinrich, J.
C1  - 1250
C2  - 26486
SP  - 180-187
TI  - Early allergic sensitizations and their relevance to atopic diseases in children aged 6 years: Results of the GINI study.
JO  - J. Invest. Allergol. Clin. Immunol.
VL  - 19
IS  - 3
PB  - Esmon Publicidad S A
PY  - 2009
SN  - 1018-9068
ER  - 

TY  - JOUR
AB  - Background: Stress has been suggested to impact the onset and exacerbation of eczema and other atopic disorders. Whether early exposure to stress-related factors might exert long-term effects remains to be clarified. Objective: The objective of this study was to investigate whether stress-related maternal factors during pregnancy are associated with childhood eczema during the first 6 years of life. Methods: Data from 3004 children from a prospective German birth cohort study (LISA) were analyzed. Information from maternity certificates and questionnaire information on unwanted pregnancy were used to evaluate stress-related maternal factors during pregnancy. Prevalence data for physician-diagnosed eczema were available up to the age of 6 years. Results: Maternal factors during pregnancy were positively associated with childhood eczema in terms of cumulative prevalence up to the age of 2 years (adjusted odds ratio, 1.48; 95% confidence interval, 0.95-2.30) after adjusting for potential confounders. Beyond the second year no increased risk was observed. Conclusions: The results of this study suggest that stress-related maternal factors during pregnancy are associated with an increased risk of childhood eczema during the first 2 years of life. The impact of postnatal stress such as parental divorce or separation on this association could not be clarified. Future studies should therefore further elucidate how prenatal and postnatal stress interact and whether prenatal stress might have a programming effect. If future studies confirm the findings of this study, reducing maternal stress during pregnancy might be a possible target in the primary prevention of eczema during childhood.
AU  - Sausenthaler, S.
AU  - Rzehak, P.
AU  - Chen, C.M.
AU  - Arck, P.*
AU  - Bockelbrink, A.*
AU  - Schäfer, T.*
AU  - Schaaf, B.*
AU  - Borte, M.*
AU  - Herbarth, O.*
AU  - Krämer, U.*
AU  - von Berg, A.*
AU  - Wichmann, H.-E.
AU  - Heinrich, J.
C1  - 1735
C2  - 26897
SP  - 481-487
TI  - Stress-related maternal factors during pregnancy in relation to childhood eczema: Results from the LISA study.
JO  - J. Invest. Allergol. Clin. Immunol.
VL  - 19
IS  - 6
PB  - Esmon Publicidad S A
PY  - 2009
SN  - 1018-9068
ER  - 

TY  - JOUR
AU  - Eberlein-König, B.*
AU  - Schmidt-Leidescher, C.*
AU  - Rakoski, J.*
AU  - Behrendt, H.
AU  - Ring, J.*
C1  - 3553
C2  - 24222
SP  - 5-10
TI  - In vitro basophil activation using CD63 expression in patients with bee and wasp venom allergy.
JO  - J. Invest. Allergol. Clin. Immunol.
VL  - 16
PY  - 2006
SN  - 1018-9068
ER  - 

TY  - JOUR
AU  - Eberlein-König, B.
AU  - Rakoski, J.*
AU  - Behrendt, H.
AU  - Ring, J.*
C1  - 1470
C2  - 21961
SP  - 10-16
TI  - Use of CD63 expression as marker of in vitro basophil activation in identifiying the culprit in insect venom allergy.
JO  - J. Invest. Allergol. Clin. Immunol.
VL  - 14
PY  - 2004
SN  - 1018-9068
ER  - 

TY  - JOUR
AU  - Fahlbusch, B.*
AU  - Gehring, U.
AU  - Richter, K.*
AU  - Wichmann, H.-E.
AU  - Heinrich, J.
C1  - 22083
C2  - 20735
SP  - 12-20
TI  - Predictors of Cat Allergen (Fel d 1) in House Dust of German Homes With/Without Cats.
JO  - J. Invest. Allergol. Clin. Immunol.
VL  - 12
PY  - 2002
SN  - 1018-9068
ER  -